An updated protocol for evaluating chest pain and managing acute coronary syndromes

Christopher R. Kelly; Ajay J. Kirtane; Jennifer Stant; Gregg W. Stone; Robert M. Minutello; S. Chiu Wong; Honeyleen Manuzon; Roxanne Gerow-Smith; Nancy Kelley; Le Roy E. Rabbani

doi:10.1097/HPC.0000000000000098

An updated protocol for evaluating chest pain and managing acute coronary syndromes

Christopher R. Kelly
, Ajay J. Kirtane
, Jennifer Stant
, Gregg W. Stone
, Robert M. Minutello
, S. Chiu Wong
, Honeyleen Manuzon
, Roxanne Gerow-Smith
, Nancy Kelley
, Le Roy E. Rabbani

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Clinical pathways can optimize care both across and within institutions, but regular updates to these pathways based on new clinical trials, professional guidelines, and Food and Drug Administration approvals are essential. Herein we describe the most recent revisions to the New York- Presbyterian Hospital (Columbia University Medical Center and Weill Cornell Medical Center) clinical pathway for acute coronary syndromes and chest pain, which incorporates novel data regarding the timing and administration of P2Y₁₂ inhibition (including the intravenous P2Y₁₂ inhibitor cangrelor) and the appropriateness of prolonged (>1 year) dual antiplatelet therapy for the secondary prevention of ischemic events.

Original language	English
Pages (from-to)	7-14
Number of pages	8
Journal	Critical Pathways in Cardiology
Volume	16
Issue number	1
DOIs	https://doi.org/10.1097/HPC.0000000000000098
State	Published - 2017
Externally published	Yes

Keywords

Acute coronary syndromes
Antiplatelet therapy
Percutaneous coronary intervention

Access to Document

10.1097/HPC.0000000000000098

Cite this

@article{36372d98441e47fd926e86ebd4d1f259,

title = "An updated protocol for evaluating chest pain and managing acute coronary syndromes",

abstract = "Clinical pathways can optimize care both across and within institutions, but regular updates to these pathways based on new clinical trials, professional guidelines, and Food and Drug Administration approvals are essential. Herein we describe the most recent revisions to the New York- Presbyterian Hospital (Columbia University Medical Center and Weill Cornell Medical Center) clinical pathway for acute coronary syndromes and chest pain, which incorporates novel data regarding the timing and administration of P2Y12 inhibition (including the intravenous P2Y12 inhibitor cangrelor) and the appropriateness of prolonged (>1 year) dual antiplatelet therapy for the secondary prevention of ischemic events.",

keywords = "Acute coronary syndromes, Antiplatelet therapy, Percutaneous coronary intervention",

author = "Kelly, \{Christopher R.\} and Kirtane, \{Ajay J.\} and Jennifer Stant and Stone, \{Gregg W.\} and Minutello, \{Robert M.\} and Wong, \{S. Chiu\} and Honeyleen Manuzon and Roxanne Gerow-Smith and Nancy Kelley and Rabbani, \{Le Roy E.\}",

year = "2017",

doi = "10.1097/HPC.0000000000000098",

language = "English",

volume = "16",

pages = "7--14",

journal = "Critical Pathways in Cardiology",

issn = "1535-282X",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - An updated protocol for evaluating chest pain and managing acute coronary syndromes

AU - Kelly, Christopher R.

AU - Kirtane, Ajay J.

AU - Stant, Jennifer

AU - Stone, Gregg W.

AU - Minutello, Robert M.

AU - Wong, S. Chiu

AU - Manuzon, Honeyleen

AU - Gerow-Smith, Roxanne

AU - Kelley, Nancy

AU - Rabbani, Le Roy E.

PY - 2017

Y1 - 2017

N2 - Clinical pathways can optimize care both across and within institutions, but regular updates to these pathways based on new clinical trials, professional guidelines, and Food and Drug Administration approvals are essential. Herein we describe the most recent revisions to the New York- Presbyterian Hospital (Columbia University Medical Center and Weill Cornell Medical Center) clinical pathway for acute coronary syndromes and chest pain, which incorporates novel data regarding the timing and administration of P2Y12 inhibition (including the intravenous P2Y12 inhibitor cangrelor) and the appropriateness of prolonged (>1 year) dual antiplatelet therapy for the secondary prevention of ischemic events.

AB - Clinical pathways can optimize care both across and within institutions, but regular updates to these pathways based on new clinical trials, professional guidelines, and Food and Drug Administration approvals are essential. Herein we describe the most recent revisions to the New York- Presbyterian Hospital (Columbia University Medical Center and Weill Cornell Medical Center) clinical pathway for acute coronary syndromes and chest pain, which incorporates novel data regarding the timing and administration of P2Y12 inhibition (including the intravenous P2Y12 inhibitor cangrelor) and the appropriateness of prolonged (>1 year) dual antiplatelet therapy for the secondary prevention of ischemic events.

KW - Acute coronary syndromes

KW - Antiplatelet therapy

KW - Percutaneous coronary intervention

UR - https://www.scopus.com/pages/publications/85013678459

U2 - 10.1097/HPC.0000000000000098

DO - 10.1097/HPC.0000000000000098

M3 - Article

C2 - 28195937

AN - SCOPUS:85013678459

SN - 1535-282X

VL - 16

SP - 7

EP - 14

JO - Critical Pathways in Cardiology

JF - Critical Pathways in Cardiology

IS - 1

ER -

An updated protocol for evaluating chest pain and managing acute coronary syndromes

Abstract

Keywords

Access to Document

Fingerprint

Cite this